Nykode Therapeutics AS (id:10313 NYKD)
3.02 NOK
Opening hours: 09:00 - 16:20 (Central European Standard Time: 12/24/2024 6:25:11 PM)
Exchange closed, opens in 14 hours 34 minutes
About Nykode Therapeutics AS
Market Capitalization 950.25M
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
| Headquarters (address) |
Oslo Research Park Oslo 0349 Norway |
| Phone | 47 22 95 81 93 |
| Website | https://nykode.com |
| Employees | 179 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | NYKD |
| Exchange | Oslo Stock Exchange |
| Currency | NOK |
| 52 week range | 1.55 - 21.40 |
| Market Capitalization | 950.25M |
| P/E trailing | -25.00 |
| P/E forward | -18.19 |
| Price/Sale | 145.83 |
| Price/Book | 5.55 |
| Beta | 1.31 |
| EPS | -1.33 |
| EPS Norway (ID:238, base:161) | 8.25 |